Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SVT 15435

Next Previous
Drug Profile

SVT 15435

Alternative Names: SVT15435

Latest Information Update: 13 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SALVAT
  • Class Antiglaucomas
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Ocular inflammation; Ocular pain

Most Recent Events

  • 13 Feb 2026 Discontinued - Phase-III for Ocular inflammation in Spain (Ophthalmic)
  • 13 Feb 2026 Discontinued - Phase-III for Ocular pain in Spain (Ophthalmic)
  • 25 Mar 2021 Phase III development is still ongoing for treatment of Ocular inflammation and Ocular pain that occurs after cataract surgery in Spain (SALVAT pipeline, March 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top